Integra LifeSciences Holdings Corporation (IART)

Market Cap	1.17B +17.3%
Revenue (ttm)	1.64B +1.2%
Net Income	-495.80M
EPS	-6.46
Shares Out	77.80M
PE Ratio	n/a
Forward PE	6.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	814,609
Open	15.11
Previous Close	15.12
Day's Range	14.83 - 15.39
52-Week Range	8.70 - 16.49
Beta	1.08
Analysts	Hold
Price Target	16.71 (+10.66%)
Earnings Date	May 5, 2026

About IART

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Aug 16, 1995
• Employees: 4,427
• Stock Exchange: NASDAQ
• Ticker Symbol: IART
• Website: https://www.integralife.com

Financial Performance

In 2025, IART's revenue was $1.64 billion, an increase of 1.53% compared to the previous year's $1.61 billion. Losses were -$516.47 million, 7337.7% more than in 2024.

Analyst Summary

According to 10 analysts, the average rating for IART stock is "Hold." The 12-month stock price target is $16.71, which is an increase of 10.66% from the latest price.

Price Target

$16.71

(10.66% upside)

Analyst Consensus: Hold